aldosterone has been researched along with Becker Muscular Dystrophy in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eplerenone treatment alone decreased a number of important muscle-specific genes." | 1.46 | Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle. ( Chadwick, JA; Gomez-Sanchez, CE; Gomez-Sanchez, EP; Hauck, JS; Rafael-Fortney, JA, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Howard, ZM | 1 |
| Rastogi, N | 1 |
| Lowe, J | 2 |
| Hauck, JS | 2 |
| Ingale, P | 1 |
| Gomatam, C | 1 |
| Gomez-Sanchez, CE | 3 |
| Gomez-Sanchez, EP | 3 |
| Bansal, SS | 1 |
| Rafael-Fortney, JA | 3 |
| Lindsay, A | 1 |
| Russell, AP | 1 |
| Chadwick, JA | 2 |
| Heier, CR | 1 |
| Yu, Q | 1 |
| Fiorillo, AA | 1 |
| Tully, CB | 1 |
| Tucker, A | 1 |
| Mazala, DA | 1 |
| Uaesoontrachoon, K | 1 |
| Srinivassane, S | 1 |
| Damsker, JM | 1 |
| Hoffman, EP | 1 |
| Nagaraju, K | 1 |
| Spurney, CF | 1 |
| Swager, SA | 1 |
| Welc, SS | 1 |
| Tidball, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Open-Label, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)[NCT05185622] | Phase 2 | 54 participants (Anticipated) | Interventional | 2022-03-21 | Recruiting | ||
| A Phase II Pilot Trial of Vamorolone vs. Placebo for the Treatment of Becker Muscular Dystrophy[NCT05166109] | Phase 2 | 39 participants (Anticipated) | Interventional | 2022-07-07 | Recruiting | ||
| A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD[NCT03777319] | Phase 1 | 2 participants (Actual) | Interventional | 2018-12-05 | Terminated (stopped due to Inability to recruit participants.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The determination of whether spironolactone has similar efficacy to glucocorticoids in improving muscle strength in steroid naïve DMD patients. This will be determined by measuring the time to complete a 100 meter timed test (100M). (NCT03777319)
Timeframe: 6 months
| Intervention | sec (Number) |
|---|---|
| Spironolactone | -0.6 |
| Prednisolone | -5.3 |
Secondary outcome measures will be Dynamometry score, which is a summation of maximum voluntary isometric contraction test values for knee flexion, knee extension, elbow flexion, and elbow extension (NCT03777319)
Timeframe: 6 months
| Intervention | kg (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elbow Flexion (Right)-Baseline | Elbow Flexion (Left)-Baseline | Elbow Extension (Right)-Baseline | Elbow Extension (Left)-Baseline | Knee Flexion (Right)-Baseline | Knee Flexion (Left)-Baseline | Knee Extension (Right)-Baseline | Knee Extension (Left)-Baseline | Elbow Flexion (Right)-Month 6 | Elbow Flexion (Left)-Month 6 | Elbow Extension (Right)-Month 6 | Elbow Extension (Left)-Month 6 | Knee Flexion (Right)-Month 6 | Knee Flexion (Left)-Month 6 | Knee Extension (Right)-Month 6 | Knee Extension (Left)-Month 6 | |
| Prednisolone | 3.6 | 4.1 | 5.3 | 4.1 | 3.3 | 3.4 | 4.8 | 5.2 | 2.9 | 3.4 | 4.3 | 3.8 | 4.1 | 3.9 | 6 | 5.1 |
| Spironolactone | 0 | 0 | 0 | 0 | 4.1 | 2.8 | 3.8 | 5.9 | 3.1 | 3.5 | 2.4 | 2.5 | 4.3 | 4.1 | 7.2 | 8.3 |
Electrolytes (Sodium, Potassium, Cloride and Carbon dioxide, mmol/L) will be measured on a monthly basis following initiation of either spironolactone or prednisolone. (NCT03777319)
Timeframe: 6 months
| Intervention | mmol/L (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium-Baseline | Sodium-Month 1 | Sodium-Month 2 | Sodium-Month 3 | Sodium-Month 4 | Sodium-Month 5 | Sodium-Month 6 | Potassium-Baseline | Potassium-Month 1 | Potassium-Month 2 | Potassium-Month 3 | Potassium-Month 4 | Potassium-Month 5 | Potassium-Month 6 | Chloride-Baseline | Chloride-Month 1 | Chloride-Month 2 | Chloride-Month 3 | Chloride-Month 4 | Chloride-Month 5 | Chloride-Month 6 | CO2-Baseline | CO2-Month 1 | CO2-Month 2 | CO2-Month 3 | CO2-Month 4 | CO2-Month 5 | CO2-Month 6 | |
| Prednisolone | 140 | 140 | 139 | 141 | 139 | 139 | 143 | 3.8 | 4 | 4.5 | 3.9 | 4.6 | 4.2 | 3.9 | 105 | 105 | 104 | 105 | 105 | 106 | 105 | 22 | 24 | 24 | 24 | 25 | 26 | 26 |
| Spironolactone | 142 | 142 | 141 | 142 | 139 | 139 | 140 | 4.5 | 4.7 | 4.2 | 4.1 | 4.5 | 4.5 | 4.3 | 103 | 109 | 107 | 103 | 103 | 103 | 101 | 29 | 22 | 25 | 27 | 28 | 28 | 26 |
5 other studies available for aldosterone and Becker Muscular Dystrophy
| Article | Year |
|---|---|
Myeloid mineralocorticoid receptors contribute to skeletal muscle repair in muscular dystrophy and acute muscle injury.
Topics: Aldosterone; Animals; Barium Compounds; Chlorides; Cytokines; Diaphragm; Disease Models, Animal; Fem | 2022 |
The unconditioned fear response in dystrophin-deficient mice is associated with adrenal and vascular function.
Topics: Aldosterone; Animals; Corticosterone; Dystrophin; Estradiol; Estrogens; Fear; Female; Humans; Male; | 2023 |
Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle.
Topics: Adolescent; Adult; Aldosterone; Blotting, Western; Cells, Cultured; Eplerenone; Humans; Male; Muscle | 2017 |
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
Topics: Aldosterone; Animals; Anti-Inflammatory Agents; Cardiomyopathies; Computer Simulation; CRISPR-Associ | 2019 |
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
Topics: Aldosterone; Animals; Anti-Inflammatory Agents; Cardiomyopathies; Computer Simulation; CRISPR-Associ | 2019 |
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
Topics: Aldosterone; Animals; Anti-Inflammatory Agents; Cardiomyopathies; Computer Simulation; CRISPR-Associ | 2019 |
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.
Topics: Aldosterone; Animals; Anti-Inflammatory Agents; Cardiomyopathies; Computer Simulation; CRISPR-Associ | 2019 |
Myeloid cells are capable of synthesizing aldosterone to exacerbate damage in muscular dystrophy.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Cytochrome P-450 CYP11B2; Disease | 2016 |